Product Description
Aprepitant is used with other medications in adults and children 6 months of age and older to prevent nausea and vomiting that may occur after receiving cancer chemotherapy treatment. It is also used with other medications in adults and children 6 months of age and older to prevent delayed nausea and vomiting that may occur several days after receiving certain chemotherapy medications. Aprepitant is not used to treat nausea and vomiting that you already have. Aprepitant is in a class of medications called antiemetics. It works by blocking the action of neurokinin, a natural substance in the brain that causes nausea and vomiting. (Sourced from: https://medlineplus.gov/druginfo/meds/a604003.html)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, China, France, Italy, Pakistan, Poland, Spain, United States
Active Clinical Trial Count: 8
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Pain|Cervical Cancer|Chronic Pain|Conduct Disorder|Depressive Disorder|Endometrial Cancer|Fallopian Tube Cancer|Malnutrition|Morphine Dependence|Neuropathic Pain|Oncology Unspecified|Other|Ovarian Cancer|Pain, Postoperative|Uterine Cancer
Phase 2: Peritoneal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2022-502983-19-00 |
ZNâc3-005 | P2 |
Recruiting |
Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer |
2027-09-01 |
2025-05-02 |
Treatments |
|
NCT06543966 |
SYH9053-002 | P3 |
Not yet recruiting |
Other |
2026-03-28 |
4% |
2024-08-10 |
Primary Endpoints|Treatments |
NCT06007586 |
CINV202306 | P3 |
Completed |
Ovarian Cancer|Endometrial Cancer|Cervical Cancer|Uterine Cancer|Fallopian Tube Cancer |
2025-06-20 |
6% |
2025-12-05 |
Primary Endpoints|Treatments |
NCT04606264 |
STUDY19030022 | P3 |
Completed |
Pain, Postoperative|Acute Pain|Morphine Dependence |
2025-03-21 |
2025-10-23 |
||
NCT06317064 |
LMRC-Aprepitant-Pain-01 | P3 |
Completed |
Neuropathic Pain|Malnutrition|Chronic Pain|Conduct Disorder|Depressive Disorder |
2024-10-31 |
10% |
2025-02-22 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
2018-000662-11 |
2018-000662-11 | P3 |
Active, not recruiting |
Oncology Unspecified |
2017-01-02 |
2025-07-06 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06932107 |
QLG2174-301 | P3 |
Completed |
Other |
2024-05-28 |
2025-04-24 |
Primary Endpoints|Treatments |
|
2018-000426-66 |
APHYPAP | P3 |
Active, not recruiting |
Unknown |
2020-03-19 |